Current Issue May 2012, Vol. 48, No. 8

EJC News Focus

Advances in the treatment of early breast cancer have revolutionised the outlook for many patients. But an important minority - around one in three - still progress to the advanced stage, which is treatable, but almost never curable. Women and men with advanced breast cancer have an illness associated with significant symptoms and one for which, in contrast to the early setting, there are few recognised therapeutic standards. An international, multidisciplinary group has now produced the first consensus guidelines, and they were presented at the European Breast Cancer Conference (Vienna, Austria; 21-24 March 2012).

Lead author Fatima Cardoso (Champalimaud Cancer Center, Lisbon, Portugal) explains why she strongly believes that widespread implementation of these guidelines will lead to better survival outcomes in advanced breast cancer.

Issue Highlights

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials
May 2012 (Vol. 48 | No. 8 | Pages 1176-1184)
Thierry Gorlia, Roger Stupp, Alba A. Brandes, Roy R. Rampling, Pierre Fumoleau, Christian Dittrich, Mario M. Campone, Chris C. Twelves, Eric Raymond, Monika E. Hegi, Denis Lacombe, Martin J. van den Bent
Over-expression of SERPINB3 in hepatoblastoma: A possible insight into the genesis of this tumour?
May 2012 (Vol. 48 | No. 8 | Pages 1219-1226)
Cristian Turato, Marie Annick Buendia, Monique Fabre, Marie Josè Redon, Sophie Branchereau, Santina Quarta, Mariagrazia Ruvoletto, Giorgio Perilongo, Michael Andreas Grotzer, Angelo Gatta, Patrizia Pontisso

Quality-of-life among head and neck cancer survivors at one year after treatment – A systematic review
14 May 2012
W.K.W. So, R.J. Chan, D.N.S. Chan, B.G.M. Hughes, S.Y. Chair, K.C. Choi, C.W.H. Chan
Abstract: Background: The importance of quality-of-life (QoL) research has been recognised over the past two decades in patients with head and neck (H&N) cancer. The aims of this systematic review...
Clear cell sarcoma of the kidney: A review
14 May 2012
S.L.M. Gooskens, R. Furtwängler, G.M. Vujanic, J.S. Dome, N. Graf, M.M. van den Heuvel-Eibrink
Abstract: Clear cell sarcoma of the kidney (CCSK) is a rare renal tumour that is observed most often in children under 3years of age. Only a few large series of CCSK have been reported and patients wi...
The EORTC QLQ-OH17: A supplementary module to the EORTC QLQ-C30 for assessment of oral health and quality of life in cancer patients
10 May 2012
Marianne Jensen Hjermstad, Mia Bergenmar, Sheila E. Fisher, Sébastien Montel, Ourania Nicolatou-Galitis, Judith Raber-Durlacher, Susanne Singer, Irma Verdonck-de Leeuw, Joachim Weis, Noam Yarom, Bente B. Herlofson
Abstract: Aims: Assessment of oral and dental problems is seldom routine in clinical oncology, despite the potential negative impact of these problems on nutritional status, social function and qualit...
Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer
09 May 2012
J. Faivre, V. Dancourt, B. Denis, E. Dorval, C. Piette, Ph. Perrin, J.M. Bidan, C. Jard, S. Jung, R. Levillain, J. Viguier, J.F. Bretagne
Abstract: Background: The aim of this study was to compare the performance of the guaiac-based faecal occult blood test (G-FOBT), with that of three immunochemical faecal occult blood tests (I-FOBT) w...
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
30 April 2012
Bradley J. Monk, Thomas J. Herzog, Stanley B. Kaye, Carolyn N. Krasner, Jan B. Vermorken, Franco M. Muggia, Eric Pujade-Lauraine, Youn C. Park, Trilok V. Parekh, Andres M. Poveda
Abstract: Aim: Trabectedin in combination with pegylated liposomal doxorubicin (PLD) improves progression-free survival (PFS) compared to PLD alone in recurrent ovarian cancer (J Clin Oncol 2010;28:31...

View More Articles in Press...

New drugs in melanoma: It’s a whole new world
September 2011 (Vol. 47 | No. 14 | Pages 2150-2157)
Alexander M.M. Eggermont, Caroline Robert
Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
October 2011 (Vol. 47 | No. 15 | Pages 2273-2281)
Gunter von Minckwitz, Kathrin Schwedler, Marcus Schmidt, Jana Barinoff, Christoph Mundhenke, Tanja Cufer, Eduard Maartense, Felix E. de Jongh, Klaus H. Baumann, Joachim Bischoff, Nadia Harbeck, Hans-Joachim Lück, Nicolai Maass, Christoph Zielinski, Michael Andersson, Robert C. Stein, Valentina Nekljudova, Sibylle Loibl, On behalf of the GBG 26/BIG 03-05 study group and participating investigators
Rare cancers are not so rare: The rare cancer burden in Europe
November 2011 (Vol. 47 | No. 17 | Pages 2493-2511)
Gemma Gatta, Jan Maarten van der Zwan, Paolo G. Casali, Sabine Siesling, Angelo Paolo Dei Tos, Ian Kunkler, Renée Otter, Lisa Licitra, Sandra Mallone, Andrea Tavilla, Annalisa Trama, Riccardo Capocaccia, The RARECARE working group
Mucinous adenocarcinomas: Poor prognosis in metastatic colorectal cancer
March 2012 (Vol. 48 | No. 4 | Pages 501-509)
Leonie J.M. Mekenkamp, Karin J. Heesterbeek, Miriam Koopman, Jolien Tol, Steven Teerenstra, Sabine Venderbosch, Cornelis J.A. Punt, Iris D. Nagtegaal
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum–gemcitabine regimen
May 2012 (Vol. 48 | No. 8 | Pages 1141-1146)
Julien Edeline, Yohann Loriot, Stephane Culine, Christophe Massard, Laurence Albiges, Aurore Blesius, Bernard Escudier, Karim Fizazi

Most Read lists are compiled every quarter.

On the Cover

New Issue Alert

Free Trial Issue

Visit EJC Supplements

New: Hormone Receptor Positive Breast Cancer Resource Centre

For all the latest research on Hormone Receptor Positive Breast Cancer, including original research articles and video interviews with leading researchers, visit our new resource centre at www.ejcancer-breast.com, edited by Professor Robert E. Coleman.

Journal Access

Full-text articles are available from 1997 to the present. Access to abstracts is complimentary. Access to full text is limited to print subscribers.

Activate Online Access

Publishing Information

European Journal of Cancer is published by Elsevier for The European Organisation for Research and Treatment of Cancer (EORTC), The European Association for Cancer Research (EACR), The European CanCer Organisation (ECCO), and The European Society of Breast Cancer Specialists (EUSOMA).

Access this journal onSciVerse ScienceDirect

Read EJC News

A new direction for breast cancer research?

EJC INTERVIEW: Obesity 'increases risk of breast cancer recurrence'

About the Journal

European Journal of Cancer Cancer (including EJC Supplements) is an international multidisciplinary oncology journal which publishes original research, editorial comments, review articles and news on basic and preclinical research, translational oncology, clinical oncology (medical, paediatric, radiation, surgical), and cancer epidemiology and prevention. More

Society Information

More Information